p21-activated kinase group II small compound inhibitor GNE-2861 perturbs estrogen receptor alpha signaling and restores tamoxifen-sensitivity in breast cancer cells

Oncotarget

Volumn 6, Issue 41, 2015, Pages 43853-43868

  Zhuang, Ting ^a   Zhu, Jian ^a   Li, Zhilun ^a   Lorent, Julie ^a   Zhao, Chunyan ^a   Dahlman Wright, Karin ^a   Strömblad, Staffan ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

ER ; PAK4; Phosphorylation; Small molecule inhibitor; Tamoxifen resistance

Indexed keywords

ESTROGEN RECEPTOR ALPHA; GNE 2861; P21 ACTIVATED KINASE 2; P21 ACTIVATED KINASE 4; P21 ACTIVATED KINASE 5; P21 ACTIVATED KINASE 6; PROTEIN SERINE THREONINE KINASE; PROTEIN SERINE THREONINE KINASE INHIBITOR; SERINE; TAMOXIFEN; UNCLASSIFIED DRUG; 1-(2-(1-(2-AMINOPYRIMIDIN-4-YL)-2-((2-METHOXYETHYL)AMINO)-1H-1,3-BENZODIAZOL-6-YL)ETHYNYL)CYCLOHEXAN-1-OL; BENZIMIDAZOLE DERIVATIVE; ENZYME INHIBITOR; ESTROGEN RECEPTOR ALPHA, HUMAN; P21 ACTIVATED KINASE; PAK4 PROTEIN, HUMAN; PYRIMIDINE DERIVATIVE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SMALL INTERFERING RNA;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER PATIENT; CANCER PROGNOSIS; CANCER RESISTANCE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SENSITIVITY; DRUG TARGETING; ENZYME ACTIVATION; GENE EXPRESSION; HUMAN; HUMAN CELL; LCC2 CELL LINE; MCF 7 CELL LINE; PAK4 GENE; POSITIVE FEEDBACK; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; BREAST TUMOR; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; FLOW CYTOMETRY; GENETIC DATABASE; GENETIC TRANSFECTION; IMMUNOBLOTTING; KAPLAN MEIER METHOD; MCF-7 CELL LINE; METABOLISM; MORTALITY; PATHOLOGY; PHYSIOLOGY; POLYMERASE CHAIN REACTION;

BENZIMIDAZOLES; BREAST NEOPLASMS; DATABASES, GENETIC; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; ESTROGEN RECEPTOR ALPHA; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOBLOTTING; KAPLAN-MEIER ESTIMATE; MCF-7 CELLS; P21-ACTIVATED KINASES; POLYMERASE CHAIN REACTION; PYRIMIDINES; RNA, SMALL INTERFERING; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SIGNAL TRANSDUCTION; TAMOXIFEN; TRANSFECTION;

EID: 84952935052     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.6081     Document Type: Article

References (58)

1. DeSantis C, Ma J, Bryan L and Jemal A. Breast cancer statistics, 2013. CA: a cancer journal for clinicians. 2014; 64:52-62.
2. Jakesz R, Smith CA, Aitken S, Huff K, Schuette W, Shackney S and Lippman M. Influence of cell proliferation and cell cycle phase on expression of estrogen receptor in MCF-7 breast cancer cells. Cancer research. 1984; 44:619-625.
3. Lin CY, Strom A, Vega VB, Kong SL, Yeo AL, Thomsen JS, Chan WC, Doray B, Bangarusamy DK, Ramasamy A, Vergara LA, Tang S, Chong A, Bajic VB, Miller LD, Gustafsson JA, et al. Discovery of estrogen receptor alpha target genes and response elements in breast tumor cells. Genome biology. 2004; 5:R66.
4. Clarke R, Leonessa F, Welch JN and Skaar TC. Cellular and molecular pharmacology of antiestrogen action and resistance. Pharmacological reviews. 2001; 53:25-71.
5. Haagenson KK, Zhang JW, Xu Z, Shekhar MP and Wu GS. Functional analysis of MKP-1 and MKP-2 in breast cancer tamoxifen sensitivity. Oncotarget. 2014; 5:1101-1110.
6. de Leeuw R, Neefjes J and Michalides R. A role for estrogen receptor phosphorylation in the resistance to tamoxifen. International journal of breast cancer. 2011; 2011:232435.
7. Knaus UG and Bokoch GM. The p21Rac/Cdc42-activated kinases (PAKs). The international journal of biochemistry & cell biology. 1998; 30:857-862.
8. Radu M, Semenova G, Kosoff R and Chernoff J. PAK signalling during the development and progression of cancer. Nature reviews Cancer. 2014; 14:13-25.
9. Bostner J, Ahnstrom Waltersson M, Fornander T, Skoog L, Nordenskjold B and Stal O. Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer. Oncogene. 2007; 26:6997-7005.
10. Holm C, Rayala S, Jirstrom K, Stal O, Kumar R and Landberg G. Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients. Journal of the National Cancer Institute. 2006; 98:671-680.
11. Barone I, Brusco L, Gu G, Selever J, Beyer A, Covington KR, Tsimelzon A, Wang T, Hilsenbeck SG, Chamness GC, Ando S and Fuqua SA. Loss of Rho GDIalpha and resistance to tamoxifen via effects on estrogen receptor alpha. Journal of the National Cancer Institute. 2011; 103:538-552.
12. Bostner J, Skoog L, Fornander T, Nordenskjold B and Stal O. Estrogen receptor-alpha phosphorylation at serine 305, nuclear p21-activated kinase 1 expression, and response to tamoxifen in postmenopausal breast cancer. Clinical cancer research: an official journal of the American Association for Cancer Research. 2010; 16:1624-1633.
13. Rayala SK, Talukder AH, Balasenthil S, Tharakan R, Barnes CJ, Wang RA, Aldaz CM, Khan S and Kumar R. P21-activated kinase 1 regulation of estrogen receptor-alpha activation involves serine 305 activation linked with serine 118 phosphorylation. Cancer research. 2006; 66:1694-1701.
14. Kok M, Zwart W, Holm C, Fles R, Hauptmann M, Van't Veer LJ, Wessels LF, Neefjes J, Stal O, Linn SC, Landberg G and Michalides R. PKA-induced phosphorylation of ERalpha at serine 305 and high PAK1 levels is associated with sensitivity to tamoxifen in ER-positive breast cancer. Breast cancer research and treatment. 2011; 125:1-12.
15. Lee SR, Ramos SM, Ko A, Masiello D, Swanson KD, Lu ML and Balk SP. AR and ER interaction with a p21-activated kinase (PAK6). Molecular endocrinology. 2002; 16:85-99.
16. Dart AE and Wells CM. P21-activated kinase 4-not just one of the PAK. European journal of cell biology. 2013; 92(4-5):129-138.
17. Callow MG, Clairvoyant F, Zhu S, Schryver B, Whyte DB, Bischoff JR, Jallal B and Smeal T. Requirement for PAK4 in the anchorage-independent growth of human cancer cell lines. The Journal of biological chemistry. 2002; 277:550-558.
18. Chen S, Auletta T, Dovirak O, Hutter C, Kuntz K, El-ftesi S, Kendall J, Han H, Von Hoff DD, Ashfaq R, Maitra A, Iacobuzio-Donahue CA, Hruban RH and Lucito R. Copy number alterations in pancreatic cancer identify recurrent PAK4 amplification. Cancer biology & therapy. 2008; 7:1793-1802.
19. Siu MK, Chan HY, Kong DS, Wong ES, Wong OG, Ngan HY, Tam KF, Zhang H, Li Z, Chan QK, Tsao SW, Stromblad S and Cheung AN. p21-activated kinase 4 regulates ovarian cancer cell proliferation, migration, and invasion and contributes to poor prognosis in patients. Proceedings of the National Academy of Sciences of the United States of America. 2010; 107:18622-18627.
20. Kimmelman AC, Hezel AF, Aguirre AJ, Zheng H, Paik JH, Ying H, Chu GC, Zhang JX, Sahin E, Yeo G, Ponugoti A, Nabioullin R, Deroo S, Yang S, Wang X, McGrath JP, et al. Genomic alterations link Rho family of GTPases to the highly invasive phenotype of pancreas cancer. Proceedings of the National Academy of Sciences of the United States of America. 2008; 105:19372-19377.
21. Liu Y, Xiao H, Tian Y, Nekrasova T, Hao X, Lee HJ, Suh N, Yang CS and Minden A. The pak4 protein kinase plays a key role in cell survival and tumorigenesis in athymic mice. Molecular cancer research: MCR. 2008; 6:1215-1224.
22. Qu J, Cammarano MS, Shi Q, Ha KC, de Lanerolle P and Minden A. Activated PAK4 regulates cell adhesion and anchorage-independent growth. Molecular and cellular biology. 2001; 21:3523-3533.
23. Wells CM, Abo A and Ridley AJ. PAK4 is activated via PI3K in HGF-stimulated epithelial cells. Journal of cell science. 2002; 115(Pt 20):3947-3956.
24. Zhang H, Li Z, Viklund EK and Stromblad S. P21-activated kinase 4 interacts with integrin alpha v beta 5 and regulates alpha v beta 5-mediated cell migration. The Journal of cell biology. 2002; 158:1287-1297.
25. Li Z, Lock JG, Olofsson H, Kowalewski JM, Teller S, Liu Y, Zhang H and Stromblad S. Integrin-mediated cell attachment induces a PAK4-dependent feedback loop regulating cell adhesion through modified integrin alpha v beta 5 clustering and turnover. Molecular biology of the cell. 2010; 21:3317-3329.
26. Li Z, Zhang H, Lundin L, Thullberg M, Liu Y, Wang Y, Claesson-Welsh L and Stromblad S. p21-activated kinase 4 phosphorylation of integrin beta5 Ser-759 and Ser-762 regulates cell migration. The Journal of biological chemistry. 2010; 285:23699-23710.
27. Ahmed T, Shea K, Masters JR, Jones GE and Wells CM. A PAK4-LIMK1 pathway drives prostate cancer cell migration downstream of HGF. Cellular signalling. 2008; 20:1320-1328.
28. Dan C, Kelly A, Bernard O and Minden A. Cytoskeletal changes regulated by the PAK4 serine/threonine kinase are mediated by LIM kinase 1 and cofilin. The Journal of biological chemistry. 2001; 276:32115-32121.
29. Gnesutta N, Qu J and Minden A. The serine/threonine kinase PAK4 prevents caspase activation and protects cells from apoptosis. The Journal of biological chemistry. 2001; 276:14414-14419.
30. Murray BW, Guo C, Piraino J, Westwick JK, Zhang C, Lamerdin J, Dagostino E, Knighton D, Loi CM, Zager M, Kraynov E, Popoff I, Christensen JG, Martinez R, Kephart SE, Marakovits J, et al. Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth. Proceedings of the National Academy of Sciences of the United States of America. 2010; 107:9446-9451.
31. Staben ST, Feng JA, Lyle K, Belvin M, Boggs J, Burch JD, Chua CC, Cui H, DiPasquale AG, Friedman LS, Heise C, Koeppen H, Kotey A, Mintzer R, Oh A, Roberts DA, et al. Back pocket flexibility provides group II p21-activated kinase (PAK) selectivity for type I 1/2 kinase inhibitors. Journal of medicinal chemistry. 2014; 57:1033-1045.
32. Ong CC, Gierke S, Pitt C, Sagolla M, Cheng CK, Zhou W, Jubb AM, Strickland L, Schmidt M, Duron SG, Campbell DA, Zheng W, Dehdashti S, Shen M, Yang N, Behnke ML, et al. Small molecule inhibition of group I p21-activated kinases in breast cancer induces apoptosis and potentiates the activity of microtubule stabilizing agents. Breast cancer research: BCR. 2015; 17:59.
33. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, Graf S, Ha G, Haffari G, Bashashati A, Russell R, McKinney S, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012; 486:346-352.
34. Gyorffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q and Szallasi Z. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast cancer research and treatment. 2010; 123:725-731.
35. Jordan VC. Tamoxifen: too much of a good thing? Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 1999; 17:2629-2630.
36. Zhang J, Wang J, Guo Q, Wang Y, Zhou Y, Peng H, Cheng M, Zhao D and Li F. LCH-7749944, a novel and potent p21-activated kinase 4 inhibitor, suppresses proliferation and invasion in human gastric cancer cells. Cancer letters. 2012; 317:24-32.
37. Brunner N, Frandsen TL, Holst-Hansen C, Bei M, Thompson EW, Wakeling AE, Lippman ME and Clarke R. MCF7/LCC2: a 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182,780. Cancer research. 1993; 53:3229-3232.
38. Johansson HJ, Sanchez BC, Mundt F, Forshed J, Kovacs A, Panizza E, Hultin-Rosenberg L, Lundgren B, Martens U, Mathe G, Yakhini Z, Helou K, Krawiec K, Kanter L, Hjerpe A, Stal O, et al. Retinoic acid receptor alpha is associated with tamoxifen resistance in breast cancer. Nature communications. 2013; 4:2175.
39. Borras M, Hardy L, Lempereur F, el Khissiin AH, Legros N, Gol-Winkler R and Leclercq G. Estradiol-induced downregulation of estrogen receptor. Effect of various modulators of protein synthesis and expression. The Journal of steroid biochemistry and molecular biology. 1994; 48:325-336.
40. Hurtado A, Holmes KA, Ross-Innes CS, Schmidt D and Carroll JS. FOXA1 is a key determinant of estrogen receptor function and endocrine response. Nature genetics. 2011; 43:27-33.
41. Carroll JS, Meyer CA, Song J, Li W, Geistlinger TR, Eeckhoute J, Brodsky AS, Keeton EK, Fertuck KC, Hall GF, Wang Q, Bekiranov S, Sementchenko V, Fox EA, Silver PA, Gingeras TR, et al. Genome-wide analysis of estrogen receptor binding sites. Nature genetics. 2006; 38:1289-1297.
42. Lin CY, Vega VB, Thomsen JS, Zhang T, Kong SL, Xie M, Chiu KP, Lipovich L, Barnett DH, Stossi F, Yeo A, George J, Kuznetsov VA, Lee YK, Charn TH, Palanisamy N, et al. Whole-genome cartography of estrogen receptor alpha binding sites. PLoS genetics. 2007; 3:e87.
43. Castles CG, Oesterreich S, Hansen R and Fuqua SA. Autoregulation of the estrogen receptor promoter. The Journal of steroid biochemistry and molecular biology. 1997; 62(2-3):155-163.
44. Hornbeck PV, Zhang B, Murray B, Kornhauser JM, Latham V and Skrzypek E. PhosphoSitePlus, 2014: mutations, PTMs and recalibrations. Nucleic acids research. 2015; 43(Database issue):D512-520.
45. Chang M. Tamoxifen resistance in breast cancer. Biomolecules & therapeutics. 2012; 20:256-267.
46. Osborne CK and Schiff R. Mechanisms of endocrine resistance in breast cancer. Annual review of medicine. 2011; 62:233-247.
47. Michalides R, Griekspoor A, Balkenende A, Verwoerd D, Janssen L, Jalink K, Floore A, Velds A, van't Veer L and Neefjes J. Tamoxifen resistance by a conformational arrest of the estrogen receptor alpha after PKA activation in breast cancer. Cancer cell. 2004; 5:597-605.
48. Zwart W, Griekspoor A, Berno V, Lakeman K, Jalink K, Mancini M, Neefjes J and Michalides R. PKA-induced resistance to tamoxifen is associated with an altered orientation of ERalpha towards co-activator SRC-1. The EMBO journal. 2007; 26:3534-3544.
49. Holm C, Kok M, Michalides R, Fles R, Koornstra RH, Wesseling J, Hauptmann M, Neefjes J, Peterse JL, Stal O, Landberg G and Linn SC. Phosphorylation of the oestrogen receptor alpha at serine 305 and prediction of tamoxifen resistance in breast cancer. The Journal of pathology. 2009; 217:372-379.
50. Wang RA, Mazumdar A, Vadlamudi RK and Kumar R. P21-activated kinase-1 phosphorylates and transactivates estrogen receptor-alpha and promotes hyperplasia in mammary epithelium. The EMBO journal. 2002; 21:5437-5447.
51. de Leeuw R, Flach K, Bentin Toaldo C, Alexi X, Canisius S, Neefjes J, Michalides R and Zwart W. PKA phosphorylation redirects ERalpha to promoters of a unique gene set to induce tamoxifen resistance. Oncogene. 2013; 32:3543-3551.
52. Rane CK and Minden A. P21 activated kinases: structure, regulation, and functions. Small GTPases. 2014; 5:e28003.
53. Ha BH, Morse EM, Turk BE and Boggon TJ. Signaling, Regulation, and Specificity of the Type II p21-activated Kinases. The Journal of biological chemistry. 2015; 290:12975-12983.
54. Zhu J, Zhao C, Kharman-Biz A, Zhuang T, Jonsson P, Liang N, Williams C, Lin CY, Qiao Y, Zendehdel K, Stromblad S, Treuter E and Dahlman-Wright K. The atypical ubiquitin ligase RNF31 stabilizes estrogen receptor alpha and modulates estrogen-stimulated breast cancer cell proliferation. Oncogene. 2014; 33:4340-4351.
55. Qiao Y, Shiue CN, Zhu J, Zhuang T, Jonsson P, Wright AP, Zhao C and Dahlman-Wright K. AP-1-mediated chromatin looping regulates ZEB2 transcription: new insights into TNFalpha-induced epithelial-mesenchymal transition in triple-negative breast cancer. Oncotarget. 2015; 6:7804-7814.
56. Matthews J, Wihlen B, Tujague M, Wan J, Strom A and Gustafsson JA. Estrogen receptor (ER) beta modulates ERalpha-mediated transcriptional activation by altering the recruitment of c-Fos and c-Jun to estrogenresponsive promoters. Molecular endocrinology. 2006; 20:534-543.
57. Zhu J, Zhao C, Zhuang T, Jonsson P, Sinha I, Williams C, Stromblad S and Dahlman-Wright K. RING finger protein 31 promotes p53 degradation in breast cancer cells. Oncogene. Advance online publication 6 July 2015; doi: 10.1038/onc.2015.260.
58. Li Q, Birkbak NJ, Gyorffy B, Szallasi Z and Eklund AC. Jetset: selecting the optimal microarray probe set to represent a gene. BMC bioinformatics. 2011; 12:474.